Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis-Reference-Cited by-同舟云学术

Effectiveness and persistence of golimumab as a second biological drug in patients with spondyloarthritis

Published:2021-04-02 Issue:13 Volume:100 Page:e25223
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Alegre-Sancho Juan J.,Juanola Xavier,Rodríguez-Heredia José M.,Manero Javier,Villa-Blanco Ignacio,Laiz Ana,Arteaga María J.,Cea-Calvo Luis,González Carlos M.

Funder

Merck Sharp & Dohme

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference34 articles.

1. Improving the management of psoriatic arthritis and axial spondyloarthritis: roundtable discussions with healthcare professionals and patients;Garrido-Cumbrera;Rheumatol Ther,2017

2. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis;Ward;Arthritis Care Res (Hoboken),2019

3. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis;Van der Heijde;Ann Rheum Dis,2017

4. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update;Gossec;Ann Rheum Dis,2016

5. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis;Zhou;J Clin Pharmacol,2007

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study;International Journal of Rheumatic Diseases;2024-03

2. Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network;Scientific Reports;2024-01-16

3. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis;Clinical Rheumatology;2023-09-26

4. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study;Rheumatology International;2023-07-05

5. Long‐term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis;Musculoskeletal Care;2022-08-22